Clearmind Medicine, SciSparc reflect on collaboration in 2023

Clearmind Medicine (CMND) reflects on the collaboration with SciSparc (SPRC) in 2023. Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office for unique combinations of future psychedelic-based compounds. The patent applications were filed as part of Clearmind’s ongoing collaboration with SciSparc, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system. The patent applications, refer to novel proprietary combinations of lysergic acid diethylamide, psilocybin, and N,N-dimethyltryptamine, 3,4-Methylenedioxymethamphetamine, Ibogaine, and Ketamine, each with Palmitoylethanolamide, the active ingredient of SciSparc’s proprietary CannAmide. The companies said,”The patent applications are part of the company’s commitment to offer patients safer and more effective treatments than those available today partly by strengthening its IP portfolio to broaden the therapeutic psychedelic toolbox for patients with mental health disorders that require transformative medicines, and developing treatments that offer synergy, efficacy and safety while reducing cost.” Clearmind has a broad IP footprint in the psychedelic space, with 51 patents in 15 utility patent families, of which twenty-six are granted patents in major jurisdictions like the US, Europe, China, and India and twenty-five patent pending applications internationally. As part of the collaboration agreement between Clearmind and SciSparc, originally announced on March 8,2022, any assets generated from the collaboration shall be jointly owned by Clearmind and SciSparc .